Zymeworks (FRA:ZA8) Short Percentage of Float


FRA:ZA8 Zymeworks Inc FRA:ZA8
66 GF Score
Price €20.30
GF Value €18.13
Valuation Modestly Overvalued
! 5 Warning Signs
View Full Analysis

What is Zymeworks Short Percentage of Float?

Short Percentage of Float is the percentage of shares shorted compared to the float.

Due to the license agreement change with our data vendor, Short Interest related data on GuruFocus will no longer be updated. Existing data will remain as-is, while new data will not be available, except for certain Australian and Canadian stocks.

FRA:ZA8 vs SRPT, BCAX, INVA: Short Percentage of Float Comparison

For the Biotechnology subindustry, Zymeworks's Short Percentage of Float, along with its competitors' market caps and Short Percentage of Float data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Zymeworks Short Percentage of Float vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Zymeworks's Short Percentage of Float distribution charts can be found below:

* The bar in red indicates where Zymeworks's Short Percentage of Float falls into.


FRA:ZA8
66GF Score
Zymeworks Inc FRA:ZA8
Short Percentage of Float is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Zymeworks (FRA:ZA8) Overvalued in 2026?

Based on GuruFocus' analysis, Zymeworks stock appears to be overvalued. The current stock price of €20.30 is trading 12% above its estimated GF Value™ of €18.13. GuruFocus considers Zymeworks to be Modestly Overvalued.

Key valuation signals for FRA:ZA8:

  • Short Percentage of Float:
  • GF Value™: €18.13 vs. price of €20.30 (12% above fair value)
  • GF Score™: 66/100 with 5 warning signs

No single metric tells the full story. See the FRA:ZA8 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Zymeworks Business Description

Other Exchanges ZYME:USAZA8:Germany
Address 108 Patriot Drive, Suite A, Middletown, DE, USA, 19709
Zymeworks Inc is a clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Its suite of therapeutic platforms and its fully integrated drug development engine enables precise engineering of differentiated therapeutic product candidates. Its clinical candidate, zanidatamab, is a novel HER2-targeted bispecific antibody currently being evaluated in multiple Phase 1, Phase 2, and pivotal clinical trials globally as a targeted treatment option for patients with solid tumors that express HER2. It is also advancing a deep preclinical pipeline in oncology and other therapeutic areas.
66GF Score

Get the complete analysis for FRA:ZA8

Short Percentage of Float is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€20.30
Price
€18.13
GF Value